Sugentech, Inc. engages in the development, manufacture, and commercializing technologies and products in the areas of multiplex immunoblot, point-of-care test, and digital healthcare based on BIO, NANO, IT, and AI convergence technology. It operates through the following business divisions: Multiplex Immunoblot, On-site Diagnosis, and Digital Healthcare. The Multiplex Immunoblot business division is a lab test product, and an in vitro diagnostic medical device used in diagnostic laboratories such as general hospitals or screening centers. The On-site Diagnosis business division commercializes in vitro diagnostic reagents for COVID-19 rapid antigen diagnostic kits and infectious diseases. The Digital Healthcare business division focuses on products used by general consumers at home. The company was founded by Mi-Jin Sohn, Eun-Kyung Kim, and Seong-Bum Yoo on December 9, 2011 and is headquartered in Daejeon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Revenue streams and regions a business earns money from
Revenue and Earnings forecasts and estimates accuracy
Dividend yield, history and sustainability
Financial position and solvency of the company